Global EGFR Inhibitors for Lung Cancer Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,480	131 Pages	GlobalInfoResearch	April, 2025	GFSH19991969

Best Price Guarantee
Price	from $3,480
Length	131 Pages
Publisher	GlobalInfoResearch
Published Date	April, 2025
SKU	GFSH19991969

According to our (Global Info Research) latest study, the global EGFR Inhibitors for Lung Cancer market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.

EGFR inhibitors play a significant role in the treatment of lung cancer, particularly in cases where the cancer cells have specific mutations in the epidermal growth factor receptor (EGFR) gene. These inhibitors are a type of targeted therapy that specifically target and block the activity of the EGFR protein, which is often overactive in cancer cells.

This report is a detailed and comprehensive analysis for global EGFR Inhibitors for Lung Cancer market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global EGFR Inhibitors for Lung Cancer market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global EGFR Inhibitors for Lung Cancer market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global EGFR Inhibitors for Lung Cancer market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global EGFR Inhibitors for Lung Cancer market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for EGFR Inhibitors for Lung Cancer

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global EGFR Inhibitors for Lung Cancer market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, AstraZeneca, Genentech (Roche Group), Beta Pharma, Mylan, Boehringer Ingelheim, Teva Pharmaceuticals, Qilu Pharmaceutical, Betta Pharmaceuticals, Haosen Pharmaceutical, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

EGFR Inhibitors for Lung Cancer market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Geftinib
Afatinib
Osimertinib
Other

Market segment by Application
Medical Care
Experiment
Others

Major players covered
Pfizer
AstraZeneca
Genentech (Roche Group)
Beta Pharma
Mylan
Boehringer Ingelheim
Teva Pharmaceuticals
Qilu Pharmaceutical
Betta Pharmaceuticals
Haosen Pharmaceutical
ARIAD Pharmaceuticals
HUTCHMED
Shanghai Ellis
Genvio Pharma
Everest Pharmaceuticals
Incepta Pharmaceuticals
Jiangsu Hengrui Medicine

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe EGFR Inhibitors for Lung Cancer product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of EGFR Inhibitors for Lung Cancer, with price, sales quantity, revenue, and global market share of EGFR Inhibitors for Lung Cancer from 2020 to 2025.

Chapter 3, the EGFR Inhibitors for Lung Cancer competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the EGFR Inhibitors for Lung Cancer breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and EGFR Inhibitors for Lung Cancer market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of EGFR Inhibitors for Lung Cancer.

Chapter 14 and 15, to describe EGFR Inhibitors for Lung Cancer sales channel, distributors, customers, research findings and conclusion.

1 Market Overview: 1.1 Product Overview and Scope; 1.2 Market Estimation Caveats and Base Year; 1.3 Market Analysis by Type; 1.3.1 Overview: Global EGFR Inhibitors for Lung Cancer Consumption Value by Type: 2020 Versus 2024 Versus 2031; 1.3.2 Geftinib; 1.3.3 Afatinib; 1.3.4 Osimertinib; 1.3.5 Other; 1.4 Market Analysis by Application; 1.4.1 Overview: Global EGFR Inhibitors for Lung Cancer Consumption Value by Application: 2020 Versus 2024 Versus 2031; 1.4.2 Medical Care; 1.4.3 Experiment; 1.4.4 Others; 1.5 Global EGFR Inhibitors for Lung Cancer Market Size & Forecast; 1.5.1 Global EGFR Inhibitors for Lung Cancer Consumption Value (2020 & 2024 & 2031); 1.5.2 Global EGFR Inhibitors for Lung Cancer Sales Quantity (2020-2031); 1.5.3 Global EGFR Inhibitors for Lung Cancer Average Price (2020-2031)
2 Manufacturers Profiles: 2.1 Pfizer; 2.1.1 Pfizer Details; 2.1.2 Pfizer Major Business; 2.1.3 Pfizer EGFR Inhibitors for Lung Cancer Product and Services; 2.1.4 Pfizer EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025); 2.1.5 Pfizer Recent Developments/Updates; 2.2 AstraZeneca; 2.2.1 AstraZeneca Details; 2.2.2 AstraZeneca Major Business; 2.2.3 AstraZeneca EGFR Inhibitors for Lung Cancer Product and Services; 2.2.4 AstraZeneca EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025); 2.2.5 AstraZeneca Recent Developments/Updates; 2.3 Genentech (Roche Group); 2.3.1 Genentech (Roche Group) Details; 2.3.2 Genentech (Roche Group) Major Business; 2.3.3 Genentech (Roche Group) EGFR Inhibitors for Lung Cancer Product and Services; 2.3.4 Genentech (Roche Group) EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025); 2.3.5 Genentech (Roche Group) Recent Developments/Updates; 2.4 Beta Pharma; 2.4.1 Beta Pharma Details; 2.4.2 Beta Pharma Major Business; 2.4.3 Beta Pharma EGFR Inhibitors for Lung Cancer Product and Services; 2.4.4 Beta Pharma EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025); 2.4.5 Beta Pharma Recent Developments/Updates; 2.5 Mylan; 2.5.1 Mylan Details; 2.5.2 Mylan Major Business; 2.5.3 Mylan EGFR Inhibitors for Lung Cancer Product and Services; 2.5.4 Mylan EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025); 2.5.5 Mylan Recent Developments/Updates; 2.6 Boehringer Ingelheim; 2.6.1 Boehringer Ingelheim Details; 2.6.2 Boehringer Ingelheim Major Business; 2.6.3 Boehringer Ingelheim EGFR Inhibitors for Lung Cancer Product and Services; 2.6.4 Boehringer Ingelheim EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025); 2.6.5 Boehringer Ingelheim Recent Developments/Updates; 2.7 Teva Pharmaceuticals; 2.7.1 Teva Pharmaceuticals Details; 2.7.2 Teva Pharmaceuticals Major Business; 2.7.3 Teva Pharmaceuticals EGFR Inhibitors for Lung Cancer Product and Services; 2.7.4 Teva Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025); 2.7.5 Teva Pharmaceuticals Recent Developments/Updates; 2.8 Qilu Pharmaceutical; 2.8.1 Qilu Pharmaceutical Details; 2.8.2 Qilu Pharmaceutical Major Business; 2.8.3 Qilu Pharmaceutical EGFR Inhibitors for Lung Cancer Product and Services; 2.8.4 Qilu Pharmaceutical EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025); 2.8.5 Qilu Pharmaceutical Recent Developments/Updates; 2.9 Betta Pharmaceuticals; 2.9.1 Betta Pharmaceuticals Details; 2.9.2 Betta Pharmaceuticals Major Business; 2.9.3 Betta Pharmaceuticals EGFR Inhibitors for Lung Cancer Product and Services; 2.9.4 Betta Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025); 2.9.5 Betta Pharmaceuticals Recent Developments/Updates; 2.10 Haosen Pharmaceutical; 2.10.1 Haosen Pharmaceutical Details; 2.10.2 Haosen Pharmaceutical Major Business; 2.10.3 Haosen Pharmaceutical EGFR Inhibitors for Lung Cancer Product and Services; 2.10.4 Haosen Pharmaceutical EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025); 2.10.5 Haosen Pharmaceutical Recent Developments/Updates; 2.11 ARIAD Pharmaceuticals; 2.11.1 ARIAD Pharmaceuticals Details; 2.11.2 ARIAD Pharmaceuticals Major Business; 2.11.3 ARIAD Pharmaceuticals EGFR Inhibitors for Lung Cancer Product and Services; 2.11.4 ARIAD Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025); 2.11.5 ARIAD Pharmaceuticals Recent Developments/Updates; 2.12 HUTCHMED; 2.12.1 HUTCHMED Details; 2.12.2 HUTCHMED Major Business; 2.12.3 HUTCHMED EGFR Inhibitors for Lung Cancer Product and Services; 2.12.4 HUTCHMED EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025); 2.12.5 HUTCHMED Recent Developments/Updates; 2.13 Shanghai Ellis; 2.13.1 Shanghai Ellis Details; 2.13.2 Shanghai Ellis Major Business; 2.13.3 Shanghai Ellis EGFR Inhibitors for Lung Cancer Product and Services; 2.13.4 Shanghai Ellis EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025); 2.13.5 Shanghai Ellis Recent Developments/Updates; 2.14 Genvio Pharma; 2.14.1 Genvio Pharma Details; 2.14.2 Genvio Pharma Major Business; 2.14.3 Genvio Pharma EGFR Inhibitors for Lung Cancer Product and Services; 2.14.4 Genvio Pharma EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025); 2.14.5 Genvio Pharma Recent Developments/Updates; 2.15 Everest Pharmaceuticals; 2.15.1 Everest Pharmaceuticals Details; 2.15.2 Everest Pharmaceuticals Major Business; 2.15.3 Everest Pharmaceuticals EGFR Inhibitors for Lung Cancer Product and Services; 2.15.4 Everest Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025); 2.15.5 Everest Pharmaceuticals Recent Developments/Updates; 2.16 Incepta Pharmaceuticals; 2.16.1 Incepta Pharmaceuticals Details; 2.16.2 Incepta Pharmaceuticals Major Business; 2.16.3 Incepta Pharmaceuticals EGFR Inhibitors for Lung Cancer Product and Services; 2.16.4 Incepta Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025); 2.16.5 Incepta Pharmaceuticals Recent Developments/Updates; 2.17 Jiangsu Hengrui Medicine; 2.17.1 Jiangsu Hengrui Medicine Details; 2.17.2 Jiangsu Hengrui Medicine Major Business; 2.17.3 Jiangsu Hengrui Medicine EGFR Inhibitors for Lung Cancer Product and Services; 2.17.4 Jiangsu Hengrui Medicine EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025); 2.17.5 Jiangsu Hengrui Medicine Recent Developments/Updates
3 Competitive Environment: EGFR Inhibitors for Lung Cancer by Manufacturer: 3.1 Global EGFR Inhibitors for Lung Cancer Sales Quantity by Manufacturer (2020-2025); 3.2 Global EGFR Inhibitors for Lung Cancer Revenue by Manufacturer (2020-2025); 3.3 Global EGFR Inhibitors for Lung Cancer Average Price by Manufacturer (2020-2025); 3.4 Market Share Analysis (2024); 3.4.1 Producer Shipments of EGFR Inhibitors for Lung Cancer by Manufacturer Revenue ($MM) and Market Share (%): 2024; 3.4.2 Top 3 EGFR Inhibitors for Lung Cancer Manufacturer Market Share in 2024; 3.4.3 Top 6 EGFR Inhibitors for Lung Cancer Manufacturer Market Share in 2024; 3.5 EGFR Inhibitors for Lung Cancer Market: Overall Company Footprint Analysis; 3.5.1 EGFR Inhibitors for Lung Cancer Market: Region Footprint; 3.5.2 EGFR Inhibitors for Lung Cancer Market: Company Product Type Footprint; 3.5.3 EGFR Inhibitors for Lung Cancer Market: Company Product Application Footprint; 3.6 New Market Entrants and Barriers to Market Entry; 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region: 4.1 Global EGFR Inhibitors for Lung Cancer Market Size by Region; 4.1.1 Global EGFR Inhibitors for Lung Cancer Sales Quantity by Region (2020-2031); 4.1.2 Global EGFR Inhibitors for Lung Cancer Consumption Value by Region (2020-2031); 4.1.3 Global EGFR Inhibitors for Lung Cancer Average Price by Region (2020-2031); 4.2 North America EGFR Inhibitors for Lung Cancer Consumption Value (2020-2031); 4.3 Europe EGFR Inhibitors for Lung Cancer Consumption Value (2020-2031); 4.4 Asia-Pacific EGFR Inhibitors for Lung Cancer Consumption Value (2020-2031); 4.5 South America EGFR Inhibitors for Lung Cancer Consumption Value (2020-2031); 4.6 Middle East & Africa EGFR Inhibitors for Lung Cancer Consumption Value (2020-2031)
5 Market Segment by Type: 5.1 Global EGFR Inhibitors for Lung Cancer Sales Quantity by Type (2020-2031); 5.2 Global EGFR Inhibitors for Lung Cancer Consumption Value by Type (2020-2031); 5.3 Global EGFR Inhibitors for Lung Cancer Average Price by Type (2020-2031)
6 Market Segment by Application: 6.1 Global EGFR Inhibitors for Lung Cancer Sales Quantity by Application (2020-2031); 6.2 Global EGFR Inhibitors for Lung Cancer Consumption Value by Application (2020-2031); 6.3 Global EGFR Inhibitors for Lung Cancer Average Price by Application (2020-2031)
7 North America: 7.1 North America EGFR Inhibitors for Lung Cancer Sales Quantity by Type (2020-2031); 7.2 North America EGFR Inhibitors for Lung Cancer Sales Quantity by Application (2020-2031); 7.3 North America EGFR Inhibitors for Lung Cancer Market Size by Country; 7.3.1 North America EGFR Inhibitors for Lung Cancer Sales Quantity by Country (2020-2031); 7.3.2 North America EGFR Inhibitors for Lung Cancer Consumption Value by Country (2020-2031); 7.3.3 United States Market Size and Forecast (2020-2031); 7.3.4 Canada Market Size and Forecast (2020-2031); 7.3.5 Mexico Market Size and Forecast (2020-2031)
8 Europe: 8.1 Europe EGFR Inhibitors for Lung Cancer Sales Quantity by Type (2020-2031); 8.2 Europe EGFR Inhibitors for Lung Cancer Sales Quantity by Application (2020-2031); 8.3 Europe EGFR Inhibitors for Lung Cancer Market Size by Country; 8.3.1 Europe EGFR Inhibitors for Lung Cancer Sales Quantity by Country (2020-2031); 8.3.2 Europe EGFR Inhibitors for Lung Cancer Consumption Value by Country (2020-2031); 8.3.3 Germany Market Size and Forecast (2020-2031); 8.3.4 France Market Size and Forecast (2020-2031); 8.3.5 United Kingdom Market Size and Forecast (2020-2031); 8.3.6 Russia Market Size and Forecast (2020-2031); 8.3.7 Italy Market Size and Forecast (2020-2031)
9 Asia-Pacific: 9.1 Asia-Pacific EGFR Inhibitors for Lung Cancer Sales Quantity by Type (2020-2031); 9.2 Asia-Pacific EGFR Inhibitors for Lung Cancer Sales Quantity by Application (2020-2031); 9.3 Asia-Pacific EGFR Inhibitors for Lung Cancer Market Size by Region; 9.3.1 Asia-Pacific EGFR Inhibitors for Lung Cancer Sales Quantity by Region (2020-2031); 9.3.2 Asia-Pacific EGFR Inhibitors for Lung Cancer Consumption Value by Region (2020-2031); 9.3.3 China Market Size and Forecast (2020-2031); 9.3.4 Japan Market Size and Forecast (2020-2031); 9.3.5 South Korea Market Size and Forecast (2020-2031); 9.3.6 India Market Size and Forecast (2020-2031); 9.3.7 Southeast Asia Market Size and Forecast (2020-2031); 9.3.8 Australia Market Size and Forecast (2020-2031)
10 South America: 10.1 South America EGFR Inhibitors for Lung Cancer Sales Quantity by Type (2020-2031); 10.2 South America EGFR Inhibitors for Lung Cancer Sales Quantity by Application (2020-2031); 10.3 South America EGFR Inhibitors for Lung Cancer Market Size by Country; 10.3.1 South America EGFR Inhibitors for Lung Cancer Sales Quantity by Country (2020-2031); 10.3.2 South America EGFR Inhibitors for Lung Cancer Consumption Value by Country (2020-2031); 10.3.3 Brazil Market Size and Forecast (2020-2031); 10.3.4 Argentina Market Size and Forecast (2020-2031)
11 Middle East & Africa: 11.1 Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Quantity by Type (2020-2031); 11.2 Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Quantity by Application (2020-2031); 11.3 Middle East & Africa EGFR Inhibitors for Lung Cancer Market Size by Country; 11.3.1 Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Quantity by Country (2020-2031); 11.3.2 Middle East & Africa EGFR Inhibitors for Lung Cancer Consumption Value by Country (2020-2031); 11.3.3 Turkey Market Size and Forecast (2020-2031); 11.3.4 Egypt Market Size and Forecast (2020-2031); 11.3.5 Saudi Arabia Market Size and Forecast (2020-2031); 11.3.6 South Africa Market Size and Forecast (2020-2031)
12 Market Dynamics: 12.1 EGFR Inhibitors for Lung Cancer Market Drivers; 12.2 EGFR Inhibitors for Lung Cancer Market Restraints; 12.3 EGFR Inhibitors for Lung Cancer Trends Analysis; 12.4 Porters Five Forces Analysis; 12.4.1 Threat of New Entrants; 12.4.2 Bargaining Power of Suppliers; 12.4.3 Bargaining Power of Buyers; 12.4.4 Threat of Substitutes; 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain: 13.1 Raw Material of EGFR Inhibitors for Lung Cancer and Key Manufacturers; 13.2 Manufacturing Costs Percentage of EGFR Inhibitors for Lung Cancer; 13.3 EGFR Inhibitors for Lung Cancer Production Process; 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel: 14.1 Sales Channel; 14.1.1 Direct to End-User; 14.1.2 Distributors; 14.2 EGFR Inhibitors for Lung Cancer Typical Distributors; 14.3 EGFR Inhibitors for Lung Cancer Typical Customers
15 Research Findings and Conclusion
16 Appendix: 16.1 Methodology; 16.2 Research Process and Data Source; 16.3 Disclaimer

PDF E-mail From Publisher:	$3,480
Multi User License (1-20) Fulfilled by Publisher:	$5,220
Global Site License Fulfilled by Publisher:	$6,960

Show additional purchase options...

Research Assistance

US: 800.298.5699

Int'l: +1.240.747.3093

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Global EGFR Inhibitors for Lung Cancer Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Global MET Inhibitors for Lung Cancer Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Pipeline Insight, 2025

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) - Pipeline Insight, 2024

EGFR Non-Small Cell Lung Cancer- Pipeline Insight, 2024

Global Lung Cancer Test Kit Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Global Generation III EGFR Inhibitors Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Research Assistance

Other tasks